Evidence map›Paper›PMID 41489697›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Serum cancer testis antigen MAGEA3-IgG serves as a diagnostic biomarker in lung adenocarcinoma.

Shuyu Huang, Yuhan Gan, Ruifang Zhong, Siying Wang, Yanli Kang, Jinhua Chen, Falin Chen, Liangyuan Chen, Jianbin You

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuyu Huang *Department of Blood Transfusion, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Yuhan Gan *Department of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China.
Ruifang ZhongDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China.
Siying WangDepartment of Blood Transfusion, The First Affiliated Hospital, Fujian Medical University, Fuzhou, 350005, China.
Yanli KangDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China.
Jinhua ChenDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China.
Falin ChenDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China.
Liangyuan ChenDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China. liangyuan039083@163.com.
Jianbin YouDepartment of Clinical Laboratory, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, No.134, East Street, Gulou District, Fuzhou, 350001, Fujian, China. 18344985224@163.com.ORCID http://orcid.org/0009-0001-5958-6240

Funding

Sponsored by Fujian Provincial Health Technology Project 2022QNA011Startup Fund for scientific research, Fujian Medical University 2022QH1076Startup Fund for scientific research, Fujian Medical University 2022QH1094
6 · The paper itself

Abstract

objectivesThis study aims to identify novel biomarkers for the early diagnosis of lung adenocarcinoma (LUAD), with the goal of facilitating early intervention to improve patient prognosis.

methodsA pilot cohort was established by collecting serum samples from 55 LUAD patients and 24 healthy controls. Based on the pilot cohort, the sample size was subsequently increased to 107 LUAD patients and 60 healthy controls, forming an expanded validation cohort. Enzyme-linked immunosorbent assay (ELISA) was employed to evaluate the expression levels of IgG and IgM autoantibodies targeting melanoma antigen gene family A (MAGEA) proteins in the pilot cohort. The autoantibody exhibiting the highest diagnostic efficacy was selected for further analysis in the expanded cohort to validate its expression in LUAD serum. Receiver operating characteristic (ROC) curve analysis was utilized to assess its potential for early diagnosis and monitoring of surgical treatment outcomes in LUAD patients.

resultsIn the pilot cohort, serum expression levels of MAGEA3-IgG, MAGEA6-IgG, MAGEA8-IgG, MAGEA9-IgG, MAGEA10-IgG, MAGEA11-IgG, and MAGEA10-IgM were significantly elevated in LUAD patients compared with healthy controls (P < 0.05), demonstrating favorable diagnostic efficacy. MAGEA3-IgG, which demonstrated the highest diagnostic efficiency in the pilot cohort, was chosen for validation in the expanded cohort. The results confirmed that the expression of MAGEA3-IgG was significantly upregulated in the serum of LUAD patients compared with healthy controls (P < 0.001), and significant differences were observed across different N stage groups (P < 0.001). Further ROC curve analysis indicated that the diagnostic performance of serum MAGEA3-IgG was marginally superior to that of CEA alone in the LUAD expanded cohort. The AUC for the combination of MAGEA3-IgG and CEA was 0.787 (95% CI 0.716-0.859), significantly enhancing the diagnostic performance. The study also demonstrated that serum levels of MAGEA3-IgG in patients with early LUAD were significantly higher than in healthy controls (P < 0.001), and the combination of MAGEA3-IgG and CEA improved the diagnostic efficacy for early LUAD (AUC = 0.748, 95% CI 0.666-0.83). In addition, serum MAGEA3-IgG exhibited strong potential for monitoring the effects of surgical treatment (AUC = 0.875, 95% CI 0.725-1).

conclusionSerum MAGEA3-IgG levels are significantly elevated in LUAD patients, and this autoantibody is anticipated to serve as a critical biomarker for early diagnosis, treatment monitoring, and prognostic evaluation in LUAD.

Indexed as

Adenocarcinoma of LungAntigens, NeoplasmBiomarkers, TumorImmunoglobulin GLung NeoplasmsNeoplasm ProteinsAdultAgedAutoantibodiesCase-Control StudiesFemaleHumansMaleMiddle AgedPilot ProjectsPrognosisAntigens, NeoplasmAutoantibodiesBiomarkers, TumorImmunoglobulin GMAGEA3 protein, humanNeoplasm ProteinsCancer-testis antigenDiagnostic biomarkerLung adenocarcinomaMAGEA3-IgGTreatment monitoring

Identifiers

PMID41489697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.